Overview

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Status:
RECRUITING

Trial end date:
2027-10-30

Target enrollment:

Participant gender:

Summary

The goal of this type of clinical trial study is to evaluate the safety and efficacy of Surufatinib combined with Carboplatin/Paclitaxel and Surufatinib combined with Olaparib as first-line and maintenance therapy for newly diagnosed high-risk ovarian cancer

Phase:

PHASE2

Details

Lead Sponsor:

Anhui Provincial Cancer Hospital

Collaborator:

Hutchison Medipharma Limited

Treatments:

Carboplatin
Paclitaxel
surufatinib